Loading
A phase 2 trial of SI-B001, Paclitaxel / nab-paclitaxel, Docetaxel in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC is a phase 2 interventional study registered as NCT05054439 by Sichuan Baili Pharmaceutical Co., Ltd., with 45 participants enrolled, started 2021-12-22 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001, Paclitaxel, docetaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Docetaxel, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares SI-B001, SystImmune / Sichuan Biokin, Docetaxel.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.